Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement…